NTRA 9620

Drug Profile

NTRA 9620

Alternative Names: NTRA-9620

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nutrinia
  • Class Insulins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity No

Highest Development Phases

  • No development reported Short bowel syndrome

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Short-bowel-syndrome(In infants) in Israel (PO, Powder)
  • 26 Aug 2016 Nutrinia plans a phase II/III trial in Short bowel syndrome (In infants) in USA and European Union , NCT02865122)
  • 18 Aug 2016 Nutrinia plans a clinical trial for Malbsorption disorders in USA and European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top